Call to Schedule Free Consultation at Over 80 Centers Worldwide!

R3 Stem Cell Nashville Now Offers MUSE Cell Therapy

Table of Contents
R3 Stem Cell Nashville announces MUSE cell therapy, featuring a laboratory sample and the Nashville, Tennessee skyline to illustrate regenerative medicine services.

A newer category of regenerative cell therapy comes to Nashville Tennessee, offered under the state’s 2026 stem cell therapy law

NASHVILLE, Tenn. — R3 Stem Cell Nashville is now offering MUSE cell therapy at its clinic at Brentwood TN (5020 Thoroughbred Lane, Brentwood TN 37027). Treatments are performed by Dr. Geneva Worthington, the clinic’s medical director and treating provider, and are provided under Tennessee’s new stem cell therapy law, which took effect July 1, 2026.

For patients in Nashville and across Middle Tennessee who are living with painful joints, tendon and ligament injuries, or chronic pain, the arrival of MUSE cells means access to an emerging regenerative therapy close to home. It also comes with what R3 believes every patient deserves: a clear explanation of what MUSE cells are, what the science does and does not yet show, and how treatment works.

What are MUSE cells?

MUSE stands for Multilineage-differentiating Stress Enduring cells. They were first identified in 2010 by Professor Mari Dezawa’s group at Tohoku University in Japan. MUSE cells are a small subpopulation of cells found in connective tissues, including bone marrow, fat, and umbilical cord tissue, and they are identified by a surface marker called SSEA-3.

In laboratory and animal studies, MUSE cells tolerate stress well, tend to migrate toward damaged tissue, and can develop into cell types from more than one tissue family. Unlike embryonic stem cells or lab-reprogrammed iPS cells, they have not been shown to form tumors in these studies. Those traits have made MUSE cells one of the more closely watched areas in regenerative medicine.

R3 Nashville uses NativeMUSE™, a MUSE cell product from Dux Bio derived from donated umbilical cord tissue. The product is FDA Compliant and is the ONLY one of its kind in the USA. There is no culturing, enzymes/additives added, and it’s full of MUSE stem cells.

The tissue is collected after healthy, full-term births with the mother’s consent. NativeMUSE™ is non-cultured, meaning the cells are not grown or expanded in a lab, and it is processed in an FDA-registered facility under federal human tissue regulations (21 CFR Part 1271). No embryonic or fetal tissue is used.

What does the research show?

MUSE cell research is promising but still early, and patients should hear that plainly.

The most advanced human studies have taken place in Japan, using a clinical-grade MUSE cell product developed for research trials. Those trials studied conditions including subacute ischemic stroke, heart attack, spinal cord injury, ALS, and a rare blistering skin disease called epidermolysis bullosa. A randomized, placebo-controlled stroke trial published in 2023 reported encouraging safety and functional results, and its authors called for larger studies to confirm them.

R3 tracks patient outcomes over time through its observational safety database, which is the kind of outcomes registry Tennessee’s new law encourages physicians to take part in.

Who might be a candidate?

Tennessee law allows physicians to offer stem cell and regenerative medicine therapies that are not FDA-approved when the treatment falls within the physician’s scope of practice. At R3 Nashville, patients most often come in for consultations about knee, hip, or shoulder arthritis, tendon and ligament injuries, back and neck pain, and other musculoskeletal conditions. Other issues are discussed during the free consultation, there are quite a few.

During your consultation, our physician will review your history and imaging, talk through conventional options you may not have tried yet, and give you an honest opinion about whether MUSE cell therapy makes sense for you.

How Tennessee law protects patients

Tennessee’s law, passed unanimously by the General Assembly and signed in May 2026, sets some of the most detailed product standards in the country. R3 Nashville follows each of them:

FDA-registered sourcing. Donor-derived cells must come from a facility that provides proof of FDA registration and follows current good manufacturing practices.

Viability standards. Each lot must show more than 90 percent live cells on its pre-thaw certificate of analysis and at least 80 percent on the post-thaw report, which the physician receives before treatment. Products must also be stored at −80°C or colder. [Confirm NativeMUSE™ lot documentation meets these thresholds.]

Lot-by-lot documentation. Each product must come with documentation that it met validated manufacturing acceptance criteria before use.

Informed consent. Before treatment, you will sign a consent form. Our physician will explain what the treatment involves, that it is not FDA-approved, the results we expect, the known risks and benefits, and the alternatives, including no treatment. We also encourage you to talk with your primary care provider first.

Safety reporting. Physicians must report any adverse event to the state medical board, and for donor-derived products, to the manufacturer within 30 days.

What to expect

Treatment begins with a consultation and a review of your medical history and any imaging. If you and the physician decide to move forward, MUSE cell treatment is an outpatient procedure. Depending on the condition, cells are delivered by injection into the affected area, typically under ultrasound guidance for accuracy. Intravenous and intranasal applications are also offered. Most patients go home the same day.

As with any injection, possible side effects include temporary soreness, swelling, or bruising at the injection site, along with rare risks such as infection or allergic reaction. Results vary from person to person, and no outcome is guaranteed. Your care team will follow up with you over the following 12 months.

Why R3

R3 Stem Cell operates more than 80 Centers of Excellence across multiple countries and has published 15 peer-reviewed research papers, including recent reviews on umbilical cord-derived cells in arthritis. R3 Nashville brings that experience to Middle Tennessee, alongside the patient protections the state now requires. Revenue from R3’s paid treatments also helps fund the company’s free programs, including free treatment for veterans and ongoing research.

“R3 offers the ONLY FDA Compliant MUSE stem cell product to patients in Nashville TN. It’s an extremely pure product and fits right in with the R3 standards for the VALUE TRIANGLE = Product Quality, Safety and most of all = Affordability!” added R3 CEO David Greene, MD, PhD, MBA.

Schedule a consultation

To learn whether MUSE cell therapy may be right for you, call (844) GET-STEM today for your free virtual consultation.

THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW.

Contact Us